Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?

MLA

Serretta, Vincenzo, et al. “Radium-223 Treatment in Castration Resistant Bone Metastatic Prostate Cancer. Should Be the Primary Tumor Always Treated?” Urologic Oncology, vol. 37, no. 12, Dec. 2019, pp. 964–69. EBSCOhost, https://doi.org/10.1016/j.urolonc.2019.08.009.

APA

Serretta, V., Valerio, M. R., Costa, R., Tripoli, V., Murabito, A., Princiotta, A., Scalici Gesolfo, C., Borsellino, N., Verderame, F., Gebbia, V., Licari, M., & Sanfilippo, C. (2019). Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated? Urologic Oncology, 37(12), 964–969. https://doi.org/10.1016/j.urolonc.2019.08.009

Chicago

Serretta, Vincenzo, Maria Rosaria Valerio, Renato Costa, Vincenzo Tripoli, Alessandra Murabito, Alessandro Princiotta, Cristina Scalici Gesolfo, et al. 2019. “Radium-223 Treatment in Castration Resistant Bone Metastatic Prostate Cancer. Should Be the Primary Tumor Always Treated?” Urologic Oncology 37 (12): 964–69. doi:10.1016/j.urolonc.2019.08.009.